Sigyn Therapeutics exchanges warrants for common stock and Series A Preferred at $0.199/share

Sigyn Therapeutics, Inc.

Entered Warrant Exchange Agreements with holders of warrants issued Oct 2020–Feb 2023.
Exchange ratio: 1 share of common stock for 2 warrants; certain holders receive Series A Preferred to cap beneficial ownership.
Series A Preferred converts to common at $0.199 per share, has same dividend/liquidation rights as common, no voting rights.
Preferred Stock issued to accredited investors in private placement exempt from registration under Section 4(a)(2).
Certificate of Designation for Series A Preferred filed with Delaware; no redemption rights, anti-dilution adjustments apply.

item 1.01 item 3.02 item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Sigyn Therapeutics, Inc.: Filed a certificate of designation establishing the rights, preferences, privileges and restrictions of a series of Preferred Stock (effective 2023-06-30).

Change: charter amendment
Effective: 2023-06-30

Exact text from the filing

On June 30, 2023, the Company filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of Preferred Stock.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sigyn Therapeutics, Inc. entered into Warrant Exchange Agreements with certain holders of warrants issued between October 20, 2020 and February 9, 2023 (effective 2023-06-30).

Action: entry
Counterparty: certain holders of warrants issued between October 20, 2020 and February 9, 2023
Effective: 2023-06-30

Exact text from the filing

On June 30, 2023, Sigyn Therapeutics, Inc. (the “Company”) entered into Warrant Exchange Agreements with certain holders of warrants issued between October 20, 2020 and February 9, 2023 (the “Warrants”) to exchange the Warrants for newly issued shares of Common Stock and Series A Preferred Stock

View on SEC.gov

Browse all governance changes →

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-023932

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.